Teng et al BLISS-BELIEVE Biomarker outcome RCT Sequential belimumab-rituximab in SLE. Certainly appears to be a serologic benefit on dsDNA, C3/4. But we need clinical parameters to correlate with this. @RheumNow #EULAR2022 OP0281 https://t.co/iEeSN0SNcr https://t.co/HN8ya4QZLU

• EULAR Abstract Archive

Manzi et al. Data on anifrolumab from TULIP studies on depression/suicidality. No effect. @RheumNow #EULAR2022 OP0282 https://t.co/5n7HBqzLkX https://t.co/fq4dxskJaA

• EULAR Abstract Archive

#POS0757 #EULAR2022 What is the perception of #lupus patients on #COVID19 recovery? A survey of 202 pts from BILAG-BR (N=20 case+, 3 hospitalised) reported full recovery from covid in only 1/3 of patients. These pts would need extra support @RheumNow https://t.co/SdH223Lfoa

Schett et al. CAR-T in SLE, case series 4 patients. Effective in inducing clinical remission in all 4 refractory patients. Looks like #rheummadness may have been (almost) correct @DavidLeverenz ! @RheumNow #EULAR2022 OP0279 https://t.co/frAU8COFs8

• EULAR Abstract Archive

More data on #iberdomide… from phase 2 study --looks like it helps #SCLE and #CCLE (but not for #ACLE) Dr. V Werth #EULAR2022 @rheumnow https://t.co/FYZlB219lf

Potential new target anti-BDCA2 Ab, #litifilimab targets pDC… impressive phase 2 studies with sig improvement in CLASI-A scores #EULAR2022 @rheumnow https://t.co/hJGx3c3Fbb

#PEARLS by Dr. Werth: 1. anti-malarials only work 50% of time for cutaneous lupus (CLE). 2. AZP is not as effective as MTX or MMF for #CLE 3. Consider RTX refractory #bullous lupus #EULAR2022 @rheumnow https://t.co/6FPJEGWioJ

Hilarious debate #EULAR2022 between Christian Dejaco and Robert Landewe on whether telemedicine is the future of rheumatology. In amongst the trash talking, here are some highlights @RheumNow

#PEARLS by EULAR President Prof Iagnocco: 1. Enthesitis can be present in 25% of #SLE patients 2. Erosions can be common and independent of ACPA/RF status 3. Active myositis is indistinguishable from IIM 4. Don't forget pain osteonecrosis/osteomyelitis #EULAR2022 @rheumnow https://t.co/8uWCw9rEve

Staggering facts by Prof Vital on #SLE and SkM Sx’s: - 50% of first Sx’s is SkM - SkM Sx are in top 3 concerns for pts - 34% pts w/SkM Sx stopped working median 4 yrs - SkM damage clusters with CVD damage #EULAR2022 @rheumnow https://t.co/NXEW3XYCQZ